Advertisement

Here's Why BioCryst Pharmaceuticals Jumped Higher Today

Here's Why BioCryst Pharmaceuticals Jumped Higher Today

Shares of BioCryst Pharmaceuticals (NASDAQ: BCRX) are up 14.5% at 1:16 p.m. after the biotech's new CFO, Anthony Doyle, purchased 54,000 shares of the company at $4.08 per share. As they say, there are many reasons an executive might feel the need to sell shares, but there's only one reason to buy: Doyle clearly thinks shares are undervalued at this point. BioCryst's valuation has increased dramatically as investors have rushed in ahead of anticipated approvals in the U.S. and Japan for its hereditary angioedema treatment, Orladeyo.